Article
Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward.
Expert opinion on investigational drugs - 1 Apr 2020
Malapelle Umberto, Muscarella Lucia Anna, Pisapia Pasquale, Rossi Antonio
Abstract excerpt
Introduction: Driver molecular aberrations, such as EGFR and BRAF mutations, ALK and ROS1 rearrangements, play an important role in the oncogenesis of non-small-cell lung cancer (NSCLC). Overall, these molecular targets select about 20% of advanced nonsquamous NSCLC Caucasian patients who can be treated with the corresponding tyrosine kinase inhibitors (TKIs). Many novel driver mutations are being or have been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.